Moiseshyn v. Commissioner: Tax Court Upholds $33,637.74 Deficiency for Unreported ESPP Gains, Dividends, and Interest
S. Tax Court has dealt a costly blow to Anthony J. 74 in capital gains, dividends, and interest income. The court’s November 4, 2026 memorandum opinion in Moiseshyn v. C. Memo.
The $33,637 Mistake: Taxpayers Face Deficiency for Overlooking ESPP Gains
The U.S. Tax Court has dealt a costly blow to Anthony J. Moiseshyn and Mai Moiseshyn, upholding a $9,424 deficiency for tax year 2021 after the IRS determined they failed to report $33,637.74 in capital gains, dividends, and interest income. The court’s November 4, 2026 memorandum opinion in Moiseshyn v. Commissioner (T.C. Memo. 2026-114) rejected the couple’s argument that their employer’s guidance—via Fidelity Investments—had already accounted for their Employee Stock Purchase Plan (ESPP) gains in their Form W-2 wages. The case underscores a critical trap for taxpayers: the mistaken belief that ESPP-related income is automatically reported by employers, even when it isn’t.
At stake was not just the $9,424 tax deficiency but the broader issue of how ESPP income is tracked and reported. The IRS, represented by Carlos S. Abarca Rodriguez and a team from the Office of Chief Counsel, argued that the Moiseshyns’ failure to report the gains—despite receiving a Form 1099-B from Fidelity for the sale of Medtronic stock—resulted in an underpayment of tax. The court’s ruling, delivered by Judge Fung, serves as a cautionary tale for the estimated 13 million U.S. employees participating in ESPPs, many of whom may unknowingly underreport gains due to complex holding period rules and employer reporting gaps. The deficiency, while substantial, could have been avoided with independent verification—a point the court implicitly underscored by rejecting the taxpayers’ reliance on third-party guidance.
The ESPP Trap: How Medtronic's Stock Plan Led to Unreported Gains
Anthony J. Moiseshyn spent 26 years as a sales representative for Medtronic PLC, a global medical technology company, earning a bimonthly salary and quarterly commissions under a term agreement. As part of his compensation package, he participated in the company’s Employee Stock Purchase Plan (ESPP), a benefit open to all full-time employees designed to encourage stock ownership and retention. The Medtronic ESPP, administered through Fidelity Brokerage Services LLC, allowed employees to contribute between 2% and 10% of their eligible compensation toward the quarterly purchase of Medtronic stock at an 85% discount to its fair market value. Participants could adjust their contribution percentages annually based on financial circumstances, and the plan’s summary materials outlined the tax consequences of acquiring and later disposing of shares, though the specifics varied depending on whether the holding period requirements were met.
Mr. Moiseshyn regularly participated in the ESPP from March 31, 2015, through March 31, 2020, accumulating an aggregate cost basis of $57,498.37 in Medtronic stock. On June 2, 2021, he sold those shares through National Financial Services LLC, which reported the transaction on Forms 1099-B as generating aggregate proceeds of $99,805.16 and a gain of $42,306.79. The tax treatment of this gain hinged on whether Mr. Moiseshyn’s sale qualified as a disqualifying disposition under the ESPP’s holding period rules—specifically, whether he had held the shares for at least two years from the offering date and one year from the purchase date. The ambiguity in the ESPP’s reporting guidance, both from Medtronic and Fidelity, left taxpayers like the Moiseshyns uncertain about whether the gain was already reflected in the $272,568 in wages and other compensation reported on Mr. Moiseshyn’s Form W-2 for 2021.
The Moiseshyns relied on their tax return preparer’s belief that all income attributable to Medtronic, including the stock sale proceeds, had already been captured in the W-2 wages reported by the company. This reliance was not without reason: the ESPP’s tax consequences were complex, and the employer’s reporting materials did not clearly delineate between compensation income and capital gains in the event of a disqualifying disposition. The preparer’s assumption—that the W-2 wages encompassed all taxable income from the ESPP transaction—reflected a common misunderstanding among employees participating in such plans, particularly when employer-provided guidance was vague or incomplete. The stakes were high: the $42,306.79 gain from the stock sale, if properly characterized as capital gain, would have required reporting on Schedule D, Capital Gains and Losses, while the $1,345 in dividend income and $146 in interest income from other sources would have needed inclusion as well. The failure to report these amounts resulted in an underpayment of tax, setting the stage for the dispute that would unfold in Tax Court.
The Dispute: Did the Form W-2 Cover All ESPP Income?
The stakes were clear: the Moiseshyns’ failure to report $32,146.74 in ESPP-related securities income, $1,345 in dividends, and $146 in interest income had triggered a deficiency notice from the IRS. The dispute hinged on whether the Form W-2 issued by Medtronic—reporting $272,568 in Box 1 wages—adequately captured all ESPP-related income for tax year 2021. The Moiseshyns argued that the W-2 was sufficient, while the IRS countered that third-party forms and the taxpayers’ lack of substantiation exposed unreported income.
The Moiseshyns’ position rested on two pillars. First, they claimed that all ESPP-related income was included in the $272,568 reported on their Form W-2, Box 1 wages. Their argument traced back to guidance from Fidelity, which stated in its tax reporting materials that “ESPP income will usually be included with . . . other compensation in [B]ox 1.” The document, admitted as Exhibit 8-P, suggested that ESPP proceeds were typically folded into wages, though it also cautioned that employees remained responsible for reporting ordinary income if their employer did not include it on the W-2. The disclaimer was critical: it undermined the Moiseshyns’ assertion that the W-2 covered all ESPP gains.
Second, the Moiseshyns testified that they lacked clear guidance from Medtronic or Fidelity on how to report the 2021 stock sale. Mr. Moiseshyn described feeling “kind of caught in the middle” between the two companies, each directing him to the other for answers. He claimed Medtronic provided no pay statement for 2021 and no documentation explaining how the ESPP proceeds were reported. His only recourse, he said, was Fidelity’s generalized guidance, which he interpreted as confirming that the W-2 included all ESPP income. To support their position, the Moiseshyns submitted Exhibits 9-P and 10-P—documents titled “2024 Employee Stock Purchase Plan Summary” and “2024 Employee Stock Purchase Plan”—but these materials pertained to later tax years and did not clarify how the 2021 ESPP stock sale was reported.
The IRS, in contrast, presented a case built on third-party reporting and the taxpayers’ failure to substantiate their claims. The agency pointed to Forms 1099-B, 1099-DIV, and 1099-INT, which evidenced unreported income from the sale of Medtronic ESPP shares, dividends from Charles Schwab and National Financial Services, and interest from the U.S. Treasury. The IRS argued that the Moiseshyns had not challenged the accuracy of these forms, nor did they provide any documentary evidence—such as a 2021 pay statement from Medtronic—to prove that the ESPP gains were included in their W-2 wages. The agency also noted that the Moiseshyns did not develop arguments about the Medtronic ESPP’s qualification under Section 423, leaving the court to assume the plan met the statutory requirements without further analysis.
The IRS further emphasized that the burden of proof rested on the Moiseshyns to demonstrate that the deficiency determination was erroneous. Under Rule 142(a) of the Tax Court’s rules, the taxpayer bears the burden of proving the IRS’s determinations incorrect, and under Welch v. Helvering, 290 U.S. 111 (1933), the IRS’s deficiency notice is presumed correct unless rebutted by sufficient evidence. The agency argued that the Moiseshyns’ reliance on Fidelity’s generalized guidance and their failure to obtain or produce Medtronic payroll records fell short of meeting this burden. The IRS also cited the Ninth Circuit’s holdings in Weimerskirch v. Commissioner, 596 F.2d 358, 361–62 (9th Cir. 1979), and Edwards v. Commissioner, 680 F.2d 1268, 1270–71 (9th Cir. 1982), which require substantive evidence linking the taxpayer to unreported income before the deficiency notice is entitled to a presumption of correctness. The Forms 1099-B, 1099-DIV, and 1099-INT, the IRS contended, provided that link, while the Moiseshyns offered nothing to rebut it.
Court Rejects Taxpayer's Reliance on Ambiguous ESPP Guidance
The Tax Court has firmly rejected the Moiseshyns’ argument that their unreported ESPP gains were excused by reliance on Fidelity’s ambiguous tax materials, upholding a $32,146.74 deficiency for tax year 2021. The court’s ruling hinged on the taxpayers’ failure to meet their burden of proof after the IRS established an evidentiary foundation linking the unreported income to the petitioners. The decision underscores the Tax Court’s willingness to scrutinize taxpayer defenses based on third-party guidance, particularly when such guidance is riddled with disclaimers and fails to provide definitive answers.
The IRS had already cleared the first hurdle in its burden-shifting framework by presenting Forms 1099-B, 1099-DIV, and 1099-INT, which the court found sufficient to establish a minimal evidentiary foundation under Ninth Circuit precedent. The court cited Delaney v. Commissioner, 743 F.2d 670, 671 (9th Cir. 1984), which holds that once the Commissioner meets this threshold, the burden shifts to the taxpayer to prove the deficiency determination was arbitrary or erroneous by a preponderance of the evidence. The Moiseshyns attempted to meet this burden with testimony and exhibits, but the court found their evidence wanting.
At the heart of the dispute was whether the $32,146.74 gain from Mr. Moiseshyn’s sale of Medtronic ESPP shares was included in the $272,568 reported in Box 1 of his 2021 Form W-2. The taxpayers argued that Fidelity’s tax reporting materials—specifically Exhibit 8-P, titled “Employee Stock Purchase Plan (Qualified)”—stated that “ESPP income will usually be included with . . . other compensation in [B]ox 1.” The court, however, dismissed this argument as insufficient, noting that Exhibit 8-P also explicitly warned that employees “remain responsible for reporting ordinary income upon disposition of ESPP shares” even if it is not reflected on a Form W-2. The disclaimer in Exhibit 8-P made it clear that Fidelity’s guidance was not definitive, leaving the Moiseshyns without concrete evidence of how Medtronic actually reported the ESPP gains.
The court’s skepticism extended to the taxpayers’ broader reliance on Fidelity as a fiduciary. Mr. Moiseshyn testified that he felt “kind of caught in the middle” between Medtronic and Fidelity, each pointing him to the other for guidance. Yet the court found no merit in this position, emphasizing that the taxpayers bore the ultimate responsibility for reporting their income correctly. The court quoted Exhibit 8-P directly to underscore this point: “employees remain responsible for reporting ordinary income even if it is not reflected on a Form W–2.” This language left no room for ambiguity—Fidelity’s materials did not absolve the Moiseshyns of their obligation to verify how Medtronic reported the ESPP gains.
The court also rejected the taxpayers’ attempt to rely on generic ESPP summaries from Medtronic—Exhibits 9-P and 10-P—which discussed the purpose of the plan but provided no clarity on how the 2021 stock sales were reported. The court noted that these exhibits did not pertain to tax year 2021 and failed to address the reporting of the stock disposition at issue. The court’s rejection of these exhibits was particularly pointed: “The documents do not clarify whether the gain from the sale of the Medtronic ESPP stock was included on Mr. Moiseshyn’s 2021 Form W–2. Even if they did, they do not pertain to the tax year at issue.”
The court’s analysis then turned to the substantive tax law governing ESPPs, specifically Section 423, which provides favorable tax treatment for stock acquired under a qualified employee stock purchase plan. The court explained that Section 423 allows employees to purchase employer stock at a discount through payroll deductions, but only if the plan meets strict requirements, including holding period mandates. Under Section 423(a)(1), employees must hold the stock for at least two years from the offering date and one year from the purchase date to avoid a “disqualifying disposition.” If the holding period is not met, the discount at purchase (the difference between the fair market value at purchase and the purchase price) is taxed as ordinary income in the year of sale. Any additional gain or loss is then treated as a short-term or long-term capital gain, depending on the holding period.
The court applied this framework to the Moiseshyns’ case and found that Mr. Moiseshyn had not met his burden of proving that the ESPP gains were included in his Form W-2. The court emphasized that the taxpayers’ reliance on Fidelity’s ambiguous materials and Medtronic’s generic summaries was insufficient to rebut the IRS’s deficiency determination. The court cited Tokarski v. Commissioner, 87 T.C. 74, 77 (1986), for the principle that the Tax Court is not required to accept self-serving testimony without supporting evidence. The Moiseshyns’ testimony about their understanding of the reporting did not suffice, as it lacked concrete documentation linking the ESPP gains to their 2021 Form W-2.
The court’s ruling is a stark reminder of the Tax Court’s insistence on rigorous substantiation, particularly in cases involving complex tax issues like ESPPs. The decision signals that taxpayers cannot rely on vague third-party guidance or employer ambiguity to escape liability for unreported income. Instead, they must independently verify how their income is reported and ensure compliance with the tax code. The court’s willingness to uphold the deficiency despite the taxpayers’ reliance on Fidelity’s materials demonstrates its commitment to enforcing the burden of proof and rejecting defenses that lack evidentiary support.
Dividends and Interest: Unchallenged Income Adds to Deficiency
The court’s scrutiny of the Moiseshyns’ tax filings extended beyond the ESPP missteps to include two smaller but unchallenged income items: $1,345 in dividends and $146.14 in interest. The IRS had determined these amounts were taxable, and the taxpayers did not dispute them. In the absence of any evidence or argument to the contrary, the court sustained the deficiency for these items as well.
Section 61(a)(7) of the Internal Revenue Code defines gross income to include dividends, while Section 61(a)(4) includes interest credited to a taxpayer. The Treasury Regulation under Section 61-7 further clarifies that interest is taxable when credited, regardless of whether it is received in cash. The Moiseshyns stipulated to receiving the dividend income from Charles Schwab and National Financial Services, as documented on Forms 1099-DIV, and conceded the $146.14 in interest income from the U.S. Treasury. With no evidence presented to challenge the IRS’s determinations, the court upheld the deficiency for these amounts. The nominal $0.14 discrepancy between the stipulated and reported interest was acknowledged but did not alter the outcome.
The court’s treatment of these unchallenged income items reinforces the broader principle that taxpayers bear the responsibility for verifying the accuracy of their reported income. Even when the amounts are relatively small, the IRS’s determinations stand unless the taxpayer introduces contrary evidence—a burden the Moiseshyns failed to meet. This aspect of the decision underscores the Tax Court’s insistence on strict compliance with reporting requirements, regardless of the size of the omission.
The Takeaway: Taxpayers Must Independently Verify ESPP Reporting
The Tax Court’s ruling in Moiseshyn v. Commissioner (T.C. Memo. 2026-11) delivers a stark warning to employees participating in employee stock purchase plans (ESPPs): relying on employer or brokerage guidance for tax reporting is a gamble with real consequences. The court sustained a $33,637 deficiency—comprising $32,146.74 in unreported securities income, $1,345 in dividend income, and $146 in interest income—after the Moiseshyns failed to substantiate their claims that their employer’s Form W-2 fully captured their ESPP gains. The decision underscores a critical principle: taxpayers bear ultimate responsibility for the accuracy of their returns, even when employers or financial institutions provide guidance that later proves incorrect.
The court’s holding hinges on the taxpayer’s failure to meet their burden of proof under Tax Court Rule 142(a), which places the onus on the taxpayer to disprove the IRS’s deficiency determination. The IRS argued—and the court agreed—that the Moiseshyns presented no evidence to rebut the deficiency notice, despite their contention that their employer’s payroll system had accounted for all ESPP-related income. The court’s blunt conclusion—"we conclude that they are moot, irrelevant, or without merit"—leaves no room for ambiguity: ambiguous employer guidance is not a shield against tax liability. This is particularly consequential for ESPP participants, who often face complex tax treatment depending on whether their disposition qualifies under Section 423 or triggers a disqualifying disposition under Section 423(c).
The decision arrives amid a broader IRS crackdown on unreported income from equity compensation, with the agency increasingly deploying data-matching programs to identify discrepancies between employer-reported wages (Form W-2) and taxpayer-reported income. The court’s treatment of the Moiseshyns’ case signals that taxpayers cannot assume their employer’s payroll system has correctly classified ESPP income. For example, if an employer reports the discount at purchase as wages but fails to account for capital gains from a later sale, the taxpayer may still owe tax on the untaxed gain. The IRS’s victory here suggests that Form W-2 alone may not be dispositive—taxpayers must independently verify whether all ESPP-related income, including capital gains from qualifying or disqualifying dispositions, has been properly reported.
The court’s insistence on strict compliance extends beyond ESPP reporting. In sustaining the deficiency, the Tax Court emphasized that even small omissions—such as the $146 in interest income—can trigger liability if the taxpayer cannot substantiate their position. This aligns with the IRS’s broader enforcement posture, where Section 6662(a) accuracy-related penalties often apply when taxpayers fail to maintain adequate records or rely on informal guidance. The Moiseshyns’ case serves as a cautionary tale: employer or brokerage statements are not a substitute for personal due diligence. Taxpayers must retain pay statements, ESPP plan documents, and transaction records to substantiate their reporting positions.
For future taxpayers, the ruling demands a proactive approach to ESPP tax compliance. Employees should:
- Review their Form W-2 and brokerage statements to confirm that all ESPP-related income—including discounts at purchase and capital gains from sales—has been reported.
- Consult a tax professional before selling ESPP shares to determine whether the transaction qualifies for favorable tax treatment under Section 423 or results in a disqualifying disposition.
- Maintain contemporaneous records of ESPP transactions, including purchase prices, sale dates, and holding periods, to satisfy the IRS’s substantiation requirements.
The Tax Court’s decision in Moiseshyn is part of a growing trend of cases where taxpayers are held accountable for relying on third-party guidance rather than verifying their own tax obligations. As ESPPs grow in popularity—particularly among tech and healthcare employees—the IRS is likely to scrutinize these transactions more closely. The court’s ruling makes clear that taxpayers cannot outsource their reporting obligations to employers or financial institutions. The $33,637 deficiency in this case is a reminder that the cost of oversight is far higher than the time spent verifying one’s own tax return.
News summaries on this site are generated with the assistance of artificial intelligence from primary source documents and are provided for educational purposes only. They are not legal advice and may contain errors; consult a qualified tax attorney about your situation and rely on the original source document. Communications are not protected by attorney client privilege until such relationship with an attorney is formed.
Related Cases
Siemens Medical Solutions USA, Inc. v. Commissioner of Internal Revenue: Tax Court Rejects IRS Limitation on Foreign Dividends Deduction
The stakes could not have been higher when Siemens Medical Solutions USA, Inc. and its consolidated subsidiaries squared off against the IRS in Tax Court this s
Eilers v. Commissioner: Full Settlement Proceeds Includible in Gross Income Despite Fee-Shifting Arguments
The Eilers’ $60,000 settlement under the Fair Credit Reporting Act (FCRA) resulted in a $11,423 federal income tax liability.
John R. Dee v. Commissioner of Internal Revenue
The Tax Court’s ruling in Dee delivers a dual message: a jurisdictional win for whistleblowers and a sharp reminder of the IRS’s unassailable discretion. After